Primary IgA Nephropathy
Nephrology·MeSH: Glomerulonephritis, IGA
Prevalence
25.0 / 100K
Incidence
2.5 / 100K/yr
2 drugs in development·2 companies·1 clinical trial
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| FILSPARI® | Travere Therapeutics, Inc. (TVTX) |
Phase 3(1)
| Drug | Company |
|---|---|
| lnp023 | Novartis AG (NVS) |
Compare drugs
Frequently asked questions
How many drugs are in development for Primary IgA Nephropathy?
BioSniper tracks 2 drugs in development for Primary IgA Nephropathy across 2 companies.
How many clinical trials target Primary IgA Nephropathy?
There are 1 clinical trial targeting Primary IgA Nephropathy tracked by BioSniper.
What is the prevalence of Primary IgA Nephropathy?
The estimated prevalence of Primary IgA Nephropathy is approximately 25.0 per 100,000 population.
Deep-dive into Primary IgA Nephropathy
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis